MedTrace Logo

Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM

NCT02906176 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-10-25

No results posted yet for this study

Summary

A clinical trail to investigate the influence of SLCO2B1 polymorphism on the pharmacokinetic characteristics of voriconazole in CYP2C19 poor metabolizers

Conditions

  • Healthy Volunteers

Interventions

DRUG

Vfend (voriconazole) intravenous infusion

Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h

DRUG

Vfend (voriconazole) tablet

Vfend (voriconazole) 200 mg tablet once

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • SeungHwan Lee, MD., PhD. · Seoul National University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2016-11-30
Completion
2017-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02906176 on ClinicalTrials.gov